Exubera Approved - Pfizer Inc - Treatment for Type 1 and Type 2 Diabetes in Adults
Exubera is a rapid-acting, dry powder human insulin that is inhaled through the mouth into the lungs prior to eating, using the handheld Exubera Inhaler. Exubera is indicated for the treatment of adult patients with diabetes mellitus, either as monotherapy, or in combination with oral agents or longer-acting insulins.Related Articles:
Pfizer and sanofi-aventis Statement on Status of Exubera - October 28, 2005
BioSante Encouraged by FDA Panel on Exubera, Superior Results of Own Inhaled Insulin Study - September 21, 2005
FDA Advisory Committee Recommends Approval of Exubera for Use in Adults With Type 1 and 2 Diabetes - September 8, 2005
Pfizer and the Sanofi-Aventis Group Seek Approval to Market Exubera in the United States - March 2, 2005
FDA Drug Approvals Archive
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Aug | Oct | Dec
